Home › Clovis Oncology reports lucitanib Phase 1/2a monotherapy study results at ASCO
 

Keywords :   


Clovis Oncology reports lucitanib Phase 1/2a monotherapy study results at ASCO

2014-05-31 19:24:01| Logistics - Topix.net

Clovis Oncology today announced results from an ongoing Phase 1/2a monotherapy study evaluating lucitanib, the Company's novel, potent inhibitor of the tyrosine kinase activity of fibroblast growth factor receptors 1 through 3 , vascular endothelial growth factor receptors 1 through 3 and platelet-derived growth factor receptors alpha and beta .

Tags: results study reports phase

Category:Transportation and Logistics

Latest from this category

All news
24.11Atlantic Tropical Weather Outlook
24.11Eastern North Pacific Tropical Weather Outlook
23.11Atlantic Tropical Weather Outlook
23.11Eastern North Pacific Tropical Weather Outlook
23.11Eastern North Pacific Tropical Weather Outlook
23.11Atlantic Tropical Weather Outlook
23.11Atlantic Tropical Weather Outlook
23.11Eastern North Pacific Tropical Weather Outlook
Transportation and Logistics »
24.11Costume
24.11BB S604ULS
24.1133
24.11 ElectronicAudioExperimentsDude Incedible
24.11 TC101 5IP 6 NS.NEO 950GH S
24.11
24.11
24.11
More »